Venture capitalists are no longer looking for a safe bet - they're on the hunt for disrupters. Managing directors from venture capital firms tell MassDevice where they're looking to place their limited resources and why the old "play-it-safe" model was broken.
MassDevice sits down with Masimo CEO Joe Kiani to discuss his career, his support for President Barack Obama, the medical device tax and what he looks for in a good investment.
Endosense CEO Jan Keltjens says the company's 3rd-generation TactiCath Quartz ablation catheter, which just won CE Mark approval in the European Union, is "the horse we’re going to ride to the finish line."
The trouble with developing an entirely new modality for treating deadly cancers of the head and trunk is that you're frequently explaining what you do and how you do it, but Novocure's tumor-treating electromagnetic fields may help patients with chemo-resistant tumors regain their lives.
When Novocure won FDA approval for its Tumor Targeting Field cancer therapy system, the company introduced the oncology world to an entire new modality for treatment.
Cancer patients today are most famliar with surgery, radiation and chemotherapy as thearpy optoins, but certain patients can also opt for Novocure's non-invasive electromagnetic therapy, which promises to stop cancer cells in their tracks without adding a new suite of side...
Rep. Bill Owens (D-N.Y.), an avid supporter of the Affordable Care Act, tells MassDevice.com why he decided this month to co-sponsor Rep. Erik Paulsen's (R-Minn.) medical device tax repeal bill.
Accuray CEO Euan Thomson discusses the finer points of robotic prostate cancer treatment and the motivation behind a head-to-head clinical trial pitting its CyberKnife radiosurgery system against Intuitive Surgical's da Vinci.